Showing posts with label SIRS. Show all posts
Showing posts with label SIRS. Show all posts

Monday, 23 March 2026

Comparative Performance of Sepsis Scoring Systems: An Indian Clinical Perspective |Chapter 7 | Medical Science: Updates and Prospects Vol. 7

 

Background: Sepsis continues to impose a major healthcare burden globally. Early identification and prompt initiation of appropriate therapy, particularly antibiotics, are critical determinants of survival. Various bedside scoring systems have been developed for early detection and prognostication of sepsis.

 

Objective: This chapter compares the predictive accuracy of Systemic Inflammatory Response Syndrome (SIRS), quick Sequential Organ Failure Assessment (qSOFA), National Early Warning Score (NEWS), and Modified Early Warning Score (MEWS) for in-hospital mortality among patients with suspected sepsis admitted to the intensive care unit (ICU).

 

Methods: This prospective comparative study was conducted in the Department of General Medicine and Critical Care at Dhiraj General Hospital, affiliated with Sumandeep Vidyapeeth University, Waghodia, Gujarat, India. A total of 188 adult patients with suspected sepsis admitted to the ICU were included. Clinical and laboratory parameters required to calculate SIRS, qSOFA, NEWS, and MEWS were recorded at admission. The Modified EWS (MEWS) score comprises five physiologic variables: systolic blood pressure (SBP), HR, RR, temperature, and mental status. The MEWS score considers the relative deviation from a patient’s normal blood pressure and urine output to identify surgical patients who would potentially benefit from intensive care. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and area under the receiver operating characteristic curve (AUROC) were calculated for each scoring system in predicting ICU mortality. Hierarchical Summary Receiver Operating Characteristic (HSROC) curve analysis was performed to compare overall prognostic accuracy.

 

Results: Among 188 patients, 42 (22.34%) died during hospitalisation. qSOFA ≥2 demonstrated the highest specificity (73.61%) but the lowest sensitivity (36.02%). SIRS ≥2 and NEWS ≥5 showed the highest sensitivity (77.78%), although SIRS had the lowest specificity (23.88%). MEWS ≥5 demonstrated balanced performance with a sensitivity of 76.36% and specificity of 63.91%. The highest discriminatory ability for ICU mortality was observed with MEWS ≥5 (AUROC 0.76; 95% CI 0.68–0.84), compared to NEWS ≥5 (AUROC 0.61), qSOFA ≥2 (AUROC 0.56), and SIRS ≥2 (AUROC 0.49). HSROC analysis confirmed the superior overall prognostic performance of MEWS. The better predictive accuracy of NEWS is most likely due to the fact that it incorporates a larger number of physiological parameters than qSOFA and SIRS, including the majority of their constituent atoms. Any scoring system for sepsis should favour better sensitivity over specificity because the consequences of false-negative results (delayed or missed therapy) are arguably much higher than those of false-positive results (unnecessary antibiotics). The AUROC for SIRS, however, was so low that it appears to have very little clinical use.

 

Conclusion: Among the four scoring systems evaluated, MEWS demonstrated the highest predictive accuracy for ICU mortality. However, none of the scoring systems achieved both high sensitivity and high specificity. These tools should therefore complement, rather than replace, comprehensive clinical assessment.

 

 

Author(s) Details

Hairya Ajaykumar Lakhani
SBKS Medical Institute and Research Centre, Vadodara, India.

 

Miloni Mineshbhai Nada
Surat Municipal Institute of Medical Education and Research (SMIMER), Affiliated to the Veer Narmad South Gujarat, University, Surat, India.

 

Aarjuv Majmundar
SBKS Medical Institute and Research Centre, Vadodara, India.

 

Sucheta Lakhani
SBKS Medical Institute and Research Centre, Vadodara, India.

 

Jitendra D Lakhani
SBKS Medical Institute and Research Centre, Vadodara, India.

 

Please see the book here :- https://doi.org/10.9734/bpi/msup/v7/7173

Monday, 14 April 2025

Response of Targeted Therapy Alongside Chemotherapy in an AML Patient with COVID-19 | Chapter 8 | Medical Science: Recent Advances and Applications Vol. 1

In this chapter, more detailed information was provided, which describes the first cycle treatment in a case of a newly diagnosed COVID-19 pneumonia in an AML patient. Pneumonia is a major cause of death among patients with leukemia. Venetoclax, a BH3-mimetic and selective BCL-2 inhibitor, is a medication used to treat adults with chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and small lymphocytic lymphoma (SLL). A 70-year-old normotensive, non-diabetic male was diagnosed with endocarditis with Aerococcus Viridans after a third molar extraction, followed by persistent fatigue, fever, weakness, nausea, and excessive sweating, especially at night. Afterwards, he was also diagnosed with AML M2/FAB (Acute myeloblastic leukemia with maturation M2). In this severe COVID-19 case, it was shown that the venetoclax treatment functioned, even in its first cycle, and moreover even without increasing the daily dose over 100 mg. One observed that the initial high value of monocytes (12620/µL) dropped after the 28-day period close to the normalization threshold (2500/µL), more exactly to 2360/µL. The positive response to venetoclax occurred even if the patient developed other comorbidities during that period, such as for example severe anemia within the disease, thrombocytopenia, and SIRS (systemic inflammatory response syndrome).

 

Author (s) Details

 

Radu Gaba
Institute of Mathematics of the Romanian Academy, RO-014700, Bucharest, Romania.

 

Please see the book here:- https://doi.org/10.9734/bpi/msraa/v1/5013

Monday, 27 July 2020

Role of Procalcitonin as Diagnostic Marker in Neonatal Sepsis and Its Correlation with Clinical, Biochemical and Haematological Profile: Scientific Study | Chapter 11 | Research Trends and Challenges in Medical Science Vol.4

Neonatal sepsis is the most common cause of morbidity and mortality in neonatal period particularly in the developing countries. Early diagnosis and treatment of sepsis is essential since a delay in treatment can lead to neonatal death. Different investigative techniques are assessed for usefulness, either singly or in combination, for the early detection of neonatal sepsis. The results of blood culture may be negative despite presence of bacterial infection. Therefore, early diagnosis is difficult, despite advanced bacteriological techniques. Inflammatory markers can also be used for early diagnosis such as C-reactive protein but it does not reliably differentiate between systemic inflammatory response and sepsis. Therefore, there is a need to identify a biomarker by which an infected neonate can be identified rapidly before the onset of life threatening symptoms and for the promt institution of antimicrobial therapy, which improves outcomes. Assessment of Procalcitonin (PCT) in the serum may help in the rapid and accurate diagnosis of sepsis as it is a reliable and specific biomarker.

Author(s) Details
Dr. Jaspreet Singh
Department of Pathology, Govt. Medical College, Amritsar, India.

View Book :- http://bp.bookpi.org/index.php/bpi/catalog/book/212